NIH clinical trial tests Remdesivir plus anti-inflammatory drug Baricitinib for COVID-19
How This Crisis Differs from the 2008–2009 Financial Crisis
Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO
3 Healthcare Stocks Under $6 That Could More Than Double: Wedbush
Patterns—and some implications—of Covid-19 financial sector policy interventions
3 Biotech Stocks Under $6 That Could More Than Double: Wedbush
State-Owned Enterprises in the Time of COVID-19
Reopening Malaysia’s economy in a new normal
Japan Plans To Approve Gilead's Remdesivir Today- Report
The Global Airline Industry Is in Even Worse Shape Than You Think
Capricor (CAPR) Shares Could Hit $10, Says Analyst
Analyst Believes Potential COVID-19 Treatment Can Push Ahersys (ATHX) Stock up to $12
AstraZeneca Wins FDA Approval For Diabetes Drug to Treat Heart Failure
AstraZeneca's blockbuster Farxiga secures landmark approval in heart failure patients, regardless of whether they have diabetes
Can The Stock Market’s ‘V’ Recovery Survive Economic Collapse?
Gilead in Talks to Ramp Up Global Supply of Remdesivir Production
Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead
The ABCs of the post-COVID economic recovery
Drugmaker Eli Lilly Partners With China’s Junshi For Covid-19 Antibody Treatment
JPMorgan's Bullish Stance on Gilead Sciences (GILD) Stock Comes to an End
DAX attacks 11,000 on COVID-19 cure hopes - sustainable?
Gilead Says Remdesivir Will Be Available To Patients This Week
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 30%
Gilead Down 5% As Q1 Earnings Spark Street Downgrades
Weekly Market Review: An April to Remember
Gilead’s Remdesivir Receives Emergency FDA Approval; Here's What This Five-Star Analyst Has To Say
SFU professor’s invention approved by FDA to help wean COVID-19 patients from ventilators
Mid-Market Update: ‘Sell in May’ adage sounds about right, Dismal Data again, Oil giants slash capex, Gold climbs higher
High-profile R&D specialist David Lebwohl jumps to new job as CMO of a pioneering CRISPR player; Troubled AMAG Pharmaceuticals taps Scott Myers as CEO
Troubled AMAG Pharmaceuticals taps Scott Myers as CEO and president; Cheryl Blanchard secures CEO title at Anika Therapeutics